Phase 1 Study of PF-07799933 Alone or With Other Medicines for Advanced Solid Tumors with BRAF Gene Changes in Participants 16 Years and Older

What this Trial Is About

Researchers are evaluating the safety and effects of a study medicine called PF-07799933 in people aged 16 years and older who have advanced solid tumors with specific BRAF gene alterations. The study focuses on participants whose cancers have progressed after prior treatments and for whom no satisfactory alternative options remain. The trial is a phase 1, open-label study aiming to assess PF-07799933 alone and in combination with other study medicines. Participants will receive PF-07799933 tablets twice daily. Depending on the study part and tumor type, participants may also receive binimetinib tablets twice daily, or cetuximab injections weekly or every two weeks. Some participants with colorectal cancer may additionally receive a chemotherapy regimen called mFOLFOX6. Treatment duration may last about two years, with close monitoring during regular clinic visits. Throughout the study, participants will have their safety evaluated by tracking dose-limiting toxicities, adverse events, laboratory and vital sign changes, and physical exams. Researchers will also monitor treatment responses and pharmacokinetics of PF-07799933. Dose adjustments or interruptions may occur due to side effects. The study includes ongoing assessments during and up to 28 days after treatment, with overall participation lasting up to two years or more.

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.